NASDAQ:TCON TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis $0.06 0.00 (0.00%) (As of 11/14/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About TRACON Pharmaceuticals Stock (NASDAQ:TCON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TRACON Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.03▼$0.1050-Day Range$0.04▼$0.2152-Week Range$0.00▼$14.75Volume37,778 shsAverage Volume126,396 shsMarket Capitalization$197,780.00P/E Ratio0.02Dividend YieldN/APrice Target$60.00Consensus RatingHold Company OverviewTRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.Read More… Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. TRACON Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks28th Percentile Overall ScoreTCON MarketRank™: TRACON Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingTRACON Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTRACON Pharmaceuticals has received no research coverage in the past 90 days.Read more about TRACON Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of TRACON Pharmaceuticals is 0.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.02.Price to Earnings Ratio vs. SectorThe P/E ratio of TRACON Pharmaceuticals is 0.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.84. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for TCON. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTRACON Pharmaceuticals does not currently pay a dividend.Dividend GrowthTRACON Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for TCON. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for TRACON Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest1 people have searched for TCON on MarketBeat in the last 30 days. MarketBeat Follows8 people have added TRACON Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TRACON Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.27% of the stock of TRACON Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.61% of the stock of TRACON Pharmaceuticals is held by institutions.Read more about TRACON Pharmaceuticals' insider trading history. Receive TCON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TCON Stock News HeadlinesTRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by Analysts at StockNews.comNovember 13 at 3:17 AM | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.comNovember 8, 2024 | americanbankingnews.comCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. November 14, 2024 | True Gold Republic (Ad)TRACON Pharma (OTC:TCON) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTRACON Pharmaceuticals Announces it Will Wind Down OperationsJuly 30, 2024 | globenewswire.comTRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma PatientsJune 11, 2024 | globenewswire.comTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Call TranscriptMay 15, 2024 | msn.comQ1 2024 TRACON Pharmaceuticals Inc Earnings CallMay 15, 2024 | finance.yahoo.comSee More Headlines TCON Stock Analysis - Frequently Asked Questions How have TCON shares performed this year? TRACON Pharmaceuticals' stock was trading at $3.5020 at the beginning of 2024. Since then, TCON stock has decreased by 98.3% and is now trading at $0.0593. View the best growth stocks for 2024 here. How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) posted its quarterly earnings data on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.13. The biopharmaceutical company earned $0.10 million during the quarter. When did TRACON Pharmaceuticals' stock split? TRACON Pharmaceuticals shares reverse split on the morning of Wednesday, April 10th 2024. The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did TRACON Pharmaceuticals IPO? TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. How do I buy shares of TRACON Pharmaceuticals? Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of TRACON Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that TRACON Pharmaceuticals investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Micron Technology (MU), Advanced Micro Devices (AMD), OPKO Health (OPK), Taiwan Semiconductor Manufacturing (TSM) and Meta Platforms (META). Company Calendar Last Earnings5/14/2024Today11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TCON CUSIPN/A CIK1394319 Webwww.traconpharma.com Phone(858) 550-0780Fax858-550-0786Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+101,080.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$3.73 Trailing P/E Ratio0.02 Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,590,000.00 Net MarginsN/A Pretax Margin145.93% Return on Equity-237.65% Return on Assets57.29% Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.66 Sales & Book Value Annual Sales$12.05 million Price / Sales0.02 Cash Flow$1.98 per share Price / Cash Flow0.03 Book Value($0.37) per share Price / Book-0.16Miscellaneous Outstanding Shares3,410,000Free Float3,228,000Market Cap$202,213.00 OptionableNo Data Beta1.43 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:TCON) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TRACON Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.